Positioning Incretin-Based and Next-Generation Obesity Management Medications: A Methodological Framework for a Series of Systematic Reviews and Network Meta-Analyses.
This paper presents a framework for evaluating obesity medications, which may help in comparing new and existing treatments in future research.
Where it sits
this study against the rest of the setmelanotide corpusSummary and findings
This paper outlines a methodological framework for systematic reviews and network meta-analyses comparing obesity management medications. It focuses on evaluating both approved and investigational compounds targeting metabolic pathways. The primary outcome of interest is percentage total body weight loss at approximately 24-26 weeks.
Abstract
<h4>Background</h4>The obesity pharmacotherapy landscape is evolving rapidly, with several approved incretin-based therapies and an expanding pipeline of investigational compounds targeting multiple metabolic pathways. Conventional evidence syntheses often struggle to accommodate differences in dose selection, treatment duration and stage of clinical development. To describe a methodological framework for a series of systematic reviews and network meta-analyses aimed at comparing approved and investigational obesity management medications (OMMs).<h4>Methods</h4>This article presents the methodological framework for a series of systematic reviews and network meta-analyses that will be conducted according to PRISMA 2020, PRISMA-NMA and PRISMA-P recommendations. Separate reviews and network meta-analyses will be performed for individual pharmacological classes of OMMs. Treatment nodes will be defined as molecule-dose combinations, selecting the highest approved dose for marketed therapies and the highest tested dose for investigational agents. Eligible studies will include randomised Phase 1-4 trials conducted in adults with overweight or obesity, with or without Type 2 diabetes. The primary outcome will be percentage total body weight loss at approximately 24-26 weeks. Risk of bias and certainty of evidence will be assessed using RoB 2 and CINeMA.<h4>Results</h4>The framework identifies 40 obesity investigational molecules that have completed at least Phase 1 development and groups them into 13 major mechanistic classes and nine approved therapies for the treatment of obesity. The present framework, therefore, encompasses 49 molecules which will serve as candidate interventions for future class-specific network meta-analyses.<h4>Conclusions</h4>This paper presents a dose-informed methodological framework for future evidence syntheses in obesity pharmacotherapy, supporting comparative evaluation and contextual positioning of next-generation OMMs.<h4>Trail registration</h4>PROSPERO-CRD420261425340.
Background
The study addresses the evolving landscape of obesity pharmacotherapy, highlighting the need for systematic reviews that can accommodate variations in dosing and treatment duration. Prior research has often struggled to synthesize evidence across different obesity management medications (OMMs). This framework aims to facilitate comparative evaluations of both approved and investigational OMMs.
Methods
The article describes a methodological framework for systematic reviews and network meta-analyses conducted according to PRISMA guidelines. It will include randomized Phase 1-4 trials in adults with overweight or obesity, with or without Type 2 diabetes. The primary outcome measure is percentage total body weight loss at approximately 24-26 weeks.
Results
The framework identifies 40 investigational obesity molecules and categorizes them into 13 mechanistic classes alongside nine approved therapies. Specific numeric findings related to treatment effects were not reported in the abstract.
Interpretation
This framework provides a structured approach for future evidence synthesis in obesity pharmacotherapy, which is necessary given the rapid development of new therapies. However, the lack of immediate findings limits its current clinical relevance. The identification of multiple investigational compounds suggests a growing interest in diverse treatment options, but the clinical significance of these compounds remains to be established through future studies.
Key findings
- Identified 40 obesity investigational molecules that have completed at least Phase 1 development.
- Grouped these into 13 major mechanistic classes and nine approved therapies for the treatment of obesity.
- The framework encompasses 49 molecules which will serve as candidate interventions for future class-specific network meta-analyses.
Limitations
- Not a primary research study, but a methodological framework.
- No immediate clinical findings reported.
- Framework does not provide data on treatment effects or outcomes.